Categories AlphaGraphs, Consumer, Earnings
Infographic: Highlights of Kellogg Company’s Q2 2022 earnings report
Kellogg Company (NYSE: K) on Thursday reported an increase in second-quarter adjusted earnings amid an increase in revenues. The company also raised its full-year earnings guidance.
Net income, adjusted for special items, rose to $1.18 per share in the most recent quarter from $1.14 per share a year earlier and came in above the forecast. Meanwhile, second-quarter unadjusted profit dropped to $326 million or $0.95 per share from $380 million or $1.11 per share in the same period of last year.
Total sales increased 9% annually to $3.86 billion during the three-month period. The latest number also topped the market’s expectations.
Check this space to read management/analysts’ comments on Kellogg’s Q2 results
“We sustained notably strong growth momentum in snacks and emerging markets, while accelerating the recovery of supply and category share in our North America cereal business, all while leveraging productivity initiatives and revenue growth management to mitigate the impact of decades-high input cost inflation,” said Steve Cahillane, Kellogg’s CEO.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Infographic: Highlights of DocuSign’s (DOCU) Q1 2024 results
DocuSign, Inc. (NASDAQ: DOCU), a leading provider of electronic signature solutions, Thursday reported first-quarter earnings. It also provided guidance for the second quarter and fiscal 2024. The company's top line
Macy’s (M): A few points to consider if you have an eye on this retailer
Shares of Macy’s, Inc. (NYSE: M) stayed in red on Thursday. The stock has dropped 22% year-to-date and 32% over the past 12 months. The retailer witnessed sales and profit
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific co-founder Dr. Jonathan Kurtis received a new patent